ALF-X System’s Debut Boosts TransEnterix (TRXC); Cognex (CGNX) Gives Upbeat Outlook


Shares of TransEnterix, Inc. (NYSEMKT:TRXC) soared more than 25% in the extended session Monday after the company said that Humanitas Hospital purchased one of its ALF-X(R) Surgical Robotic System, representing the first global sale of the CE-Marked multi-port robotic system.

TRXC stock closed at $1.30, down $0.05 (or -3.70%) and 607,144 shares of the medical device company changed hands during the day

TransEnterix, which focuses on the development and commercialization of surgical robotic systems, has 114.78M Shares Outstanding, Market Capitalization (intraday) of $149.21M and TRXC stock 52-week range is between $1.03 and $6.10 per share



Cognex Corp. (Nasdaq:CGNX) shares climbed over 12% in after-hours trading Monday as the company delivered in its financial results quarterly profit and revenue numbers above Wall Street analysts’ expectations

For the second quarter 2016, Cognex posted revenue of $147.27 million and net income of $43.01 million or $0.50 per diluted share, topping the Capital IQ Consensus estimate of $0.44 earings per share on revenues of $138.11 million for the period

The machine vision systems provider said that it expects third quarter revenue to be in a range from $142 million to $147 million, which represents substantial growth versus the same quarter the prior year and easily surpasses the Capital IQ Consensus Estimate of $127.61 million for the period

CGNX stock finished the regular session in positive territory by 0.33% (or +$0.15) at $45.32 with 861,624 shares traded, a large increase in activity versus its average volume (3m) of 381,920

Cognex has 85.05M Shares Outstanding. At close on Monday, the company had a Market Capitalization of $3.85B and CGNX stock one-year range was from $28.01 to $45.74 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at